Compare DexCom, Inc. (DXCM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? DexCom, Inc. trades at $86 (market cap $31.51B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: DexCom, Inc. is far larger — about 6.3× Travere Therapeutics Inc. Common Stock's market cap, and DexCom, Inc. is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| DXCM | TVTX | |
|---|---|---|
Market Cap | $31.51B | $5.02B |
Volume | 3,480,291 | 2,060,842 |
Sector | Health | Health |
52-Week High | $92.34 | $67.52 |
52-Week Low | $54.84 | $26.79 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $30.96B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $85.06, down 1.0% on the day, with a bullish technical signal and strong fundamental growth. Revenue reached $4.66B in 2025 with a net income margin of 17.93%, and the company has beaten EPS estimates for the last three quarters. Recent news highlights expansion in Type 2 diabetes care and executive promotions, supporting positive sentiment.
The outlook is positive with a consensus price target of $96.14, implying 13% upside. Risks include competition and reimbursement challenges, but robust earnings growth and institutional backing provide a solid foundation for long-term investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
